Glycobiosciences, Inc. v. Vichy Laboratories, Sa

CourtDistrict Court, District of Columbia
DecidedJanuary 11, 2023
DocketCivil Action No. 2022-1264
StatusPublished

This text of Glycobiosciences, Inc. v. Vichy Laboratories, Sa (Glycobiosciences, Inc. v. Vichy Laboratories, Sa) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Glycobiosciences, Inc. v. Vichy Laboratories, Sa, (D.D.C. 2023).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

GLYCOBIOSCIENCES, INC.,

Plaintiff, Civil Action No. 22-1264 (BAH)

v. Chief Judge Beryl A. Howell

VICHY LABORATORIES, S.A. and

L’ORÉAL, S.A.

Defendants.

MEMORANDUM OPINION AND ORDER

Plaintiff Glycobiosciences, Inc., a Canadian cosmetic and pharmaceutical company, owns

two patented formulae that are allegedly being infringed by Vichy Laboratories, S.A. and L’Oréal,

S.A. (collectively, “defendants”). 1 Plaintiff sued defendants, alleging claims of patent

infringement. See 35 U.S.C. §101 et. seq. Defendants now move to dismiss, claiming, inter alia,

that personal jurisdiction is lacking over them in this judicial district. For the reasons below,

defendants’ motion to dismiss is granted, without prejudice.

I. BACKGROUND

The relevant factual and procedural background is summarized below.

A. Factual Background

1 Vichy Laboratories S.A. is named as a defendant in this action, but defendants clarify that no entity with that name exists and that an entity named “Vichy LLC” is wholly owned by L’Oréal USA with “Vichy” used as a brand name. Defs.’Mot. at 5 (explaining that “Vichy” is “a brand used by L’Oréal USA and there is a separate LLC—named Vichy LLC—for that brand. L’Oréal USA is the only member of Vichy LLC and the LLC has no employees or operations.”). Plaintiff concedes that Vichy Laboratories S.A. does not exist, and Vichy LLC is merely part of L’Oréal USA. See Pl’s Opp’n at 1 n.1 (“Defendant Vichy Laboratories is apparently a non-entity that is simply a brand name of Defendant L’Oréal S.A. . . . Thus[,] the Defendants collapse back into L’Oréal S.A.”). Consequently, assessment of personal jurisdiction focuses only on L’Oréal S.A.

1 Plaintiff is a successful Canadian cosmetic and pharmaceutical company that owns the

following two patents at issue: (1) Patent No. 9,821,005, issued by the U.S. Patent and Trademark

Office (“USPTO”) to plaintiff on November 21, 2017, for the formula of a gel containing specific

percentages of bio-fermented sodium hyaluronate, hydroxyethylcellulose, polyethylene glycol,

methylparaben, and water, Pls.’ Compl. (“Compl.”), ¶¶ 1, 12, 17, ECF No. 1; and (2) Patent No.

10,322,142, issued by USPTO to plaintiff on June 18, 2019, for the formula of a polymer matrix

composed of specific percentages of bio-fermented sodium hyaluronate, non-ionic polymer,

polyethylene glycol, and water, along with the inclusion “of an active therapeutic ingredient in

addition to the Hyaluronic Acid,” id. ¶¶ 1, 13, 18. Both patents expire on August 5, 2035. Id.

¶ 13.

L’Oréal S.A., a corporation with its principal place of business and headquarters in Clichy,

France, allegedly sells and distributes products using formulas similar to those that plaintiff has

patented. See Id. ¶ 3, 19. Specifically, L’Oréal S.A. manufactures, distributes, and sells three

cosmetics under the name Revitalift, which “contain high concentrations of Hyaluronic Acid in a

Polymer matrix which includes a non-ionic polymer and are formulations that have all of the

elements of one or more of the claims of the Glyco Patents and/or have formulae that are equivalent

to the claimed formulas.” Id. ¶ 14. Likewise, “Vichy manufactures and sells” three products under

the name “Liftactiv,” each “contain[ing] high concentrations of Hyaluronic Acid in a Polymer

matrix which includes a non-ionic polymer and are formulations that have all of the elements of

one or more of the claims of the Glyco Patents and/or have formulae that are equivalent to the

claimed formulas.” Id. ¶ 15.

L’Oréal S.A. sells and distributes these products in the United States, including in the

District of Columbia, exclusively through L’Oréal d/b/a L’Oréal USA (“L’Oréal USA”). See id.

2 ¶¶ 3–4, 6. Apart from the contacts of L’Oréal USA, the only other contact that L’Oréal S.A. has

in the United States is allegedly that an “Assistant Vice President – DIPI International Head of

Instrumental Cosmetics & Digital,” named Dr. Roy P. Diaz, works out of an office located at 111

Terminal Avenue in Clark, New Jersey. Pl.’s Opp’n, Ex. C at 1 (Email, dated on March 22, 2022,

to plaintiff’s representative from Dr. Diaz with the latter’s job title and office address in the

signature block of the email) (“Diaz Email”), ECF No. 22-1.

B. Procedural Background

In an effort to resolve the dispute amicably, plaintiff contacted and presented the two patent

licenses at issue to L’Oréal S.A., with a request that defendant stop selling the allegedly patent-

infringing products. See Compl. ¶¶ 16, 24, 30, 36, 40. L’Oréal S.A. declined the request, see id.,

prompting plaintiff to initiate the instant lawsuit, claiming that defendants willfully infringed both

patents. Id. at 10, ¶¶ A-G. Plaintiff seeks a permanent injunction, compensatory damages,

enhanced damages, attorneys’ fees, prejudgment interest, and post judgment interest. Id. at 10, ¶¶

H-M.

Defendants timely moved to dismiss for lack of personal jurisdiction, improper service,

and improper venue, see Defs.’ Mot. to Dismiss (“Defs.’ Mot”), ECF No. 10, which motion

plaintiff opposes, see Pl.’s Opp’n to. Mot. to Dismiss (“Pl.’s Opp’n”), ECF No. 12. With briefing

completed, see Defs.’ Reply Mem. in Supp. Mot. to Dismiss (“Defs.’ Reply”), ECF No. 13,

defendants’ motion is now ripe for resolution.

II. LEGAL STANDARD

“Personal jurisdiction is ‘an essential element of the jurisdiction of a district . . . court,’

without which the court is ‘powerless to proceed to an adjudication.’” Jankovic v. Int’l Crisis

Grp., 494 F.3d 1080, 1086 (D.C. Cir. 2007) (alteration in original) (quoting Ruhrgas AG v.

Marathon Oil Co., 526 U.S. 574, 584 (1999)). To survive a motion to dismiss for lack of personal 3 jurisdiction, under Federal Rule of Civil Procedure 12(b)(2), the plaintiff must “make a prima facie

showing of the pertinent jurisdictional facts.” Livnat v. Palestinian Auth., 851 F.3d 45, 56–57

(D.C. Cir. 2017) (quoting First Chi. Int’l v. United Exch. Co., 836 F.2d 1375, 1378 (D.C. Cir.

1988)). The prima facie showing requires specific factual allegations connecting each defendant

to the forum. First Chi. Int'l, 836 F.2d at 1378. While the complaint’s factual allegations must be

accepted as true, and all reasonable inferences must be drawn in plaintiff’s favor, Bernhardt v.

Islamic Republic of Iran, 47 F.4th 856, 861 (D.C. Cir. 2022), mere conclusory statements and bare

allegations are insufficient, Livnat, 851 F.3d at 57.

Unlike on a motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6), the

court “may consider materials outside the pleadings in deciding whether to grant a motion to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Ruhrgas Ag v. Marathon Oil Co.
526 U.S. 574 (Supreme Court, 1999)
Helmer, John v. Doletskaya, Elena
393 F.3d 201 (D.C. Circuit, 2004)
Mwani, Odilla Mutaka v. Bin Ladin, Usama
417 F.3d 1 (D.C. Circuit, 2005)
Jankovic v. International Crisis Group
494 F.3d 1080 (D.C. Circuit, 2007)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
Victor Herbert v. National Academy of Sciences
974 F.2d 192 (D.C. Circuit, 1992)
Johnson-Tanner v. First Cash Financial Services, Inc.
239 F. Supp. 2d 34 (District of Columbia, 2003)
BPA International, Inc. v. Kingdom of Sweden
281 F. Supp. 2d 73 (District of Columbia, 2003)
United States Ex Rel. Scollick v. Narula
215 F. Supp. 3d 26 (District of Columbia, 2016)
Rivka Livnat v. Palestinian Authority
851 F.3d 45 (D.C. Circuit, 2017)
Mary Erwin-Simpson v. AirAsia Berhad
985 F.3d 883 (D.C. Circuit, 2021)
Ford Motor Co. v. Montana Eighth Judicial Dist.
592 U.S. 351 (Supreme Court, 2021)
Joshua Atchley v. Astrazeneca UK Limited
22 F.4th 204 (D.C. Circuit, 2022)
Dana Bernhardt v. Islamic Republic of Iran
47 F.4th 856 (D.C. Circuit, 2022)

Cite This Page — Counsel Stack

Bluebook (online)
Glycobiosciences, Inc. v. Vichy Laboratories, Sa, Counsel Stack Legal Research, https://law.counselstack.com/opinion/glycobiosciences-inc-v-vichy-laboratories-sa-dcd-2023.